组成

状态

容量

(A) 抗体固相化 96 孔板

洗净后使用

96   wells（8×12）/1 块

(B) GLP-1标准溶液（500 pg/mL）

稀释后使用

200 μL/1 瓶

(C) 缓冲液

即用

60 mL/1 瓶

(D)生物素结合抗GLP-1抗体

稀释后使用

100 μL/1 瓶

(E) 过氧化物・抗生物素蛋白结合物

稀释后使用

100 μL/1 瓶

(F) 显色液（TMB）

即用

12 mL/1 瓶

(H) 反应终止液（1M H₂SO₄）※小心轻放

即用

12 mL/1 瓶

( I ) 浓缩洗净液（10×）

稀释后使用

100 mL/1 瓶

封板膜

4 张

使用说明书

1 份

动物类型

对象物质

反应性和反应率（％）

Mouse/Rat

GLP-1(7-36)amide

100

GLP-1(7-37)

<   0.1

GLP-1(1-37)

―

GLP-1(9-36)amide

―

GLP-2

―

Glucagon(1-29)

―

Insulin

―

Secretin

―

GIP

―

VIP

―

GRF

―

Bovine

Glucagon(1-29)

―

VIP

―

Porcine

Glucagon(1-29)

―

VIP

―

样品

A

B

1

23.7

6.44

2

23.2

5.97

3

23.4

6.39

4

24.0

5.87

5

24.1

6.44

mean

23.7

6.22

SD

0.35

0.28

CV(%)

1.5

4.5

测量日/样品

E

F

第０天

25.1

6.31

第１天

25.1

6.16

第２天

25.0

6.24

第３天

25.0

6.37

mean

25.0

6.27

SD

0.03

0.09

CV(%)

0.13

1.4

添加量

实测值

回收量

回收率(%)

0.00

3.93

–

–

3.26

7.28

3.35

103

6.51

10.3

6.37

97.8

8.14

12.1

8.17

100

添加量

实测值

回收量

回收率(%)

0.00

11.8

–

–

7.16

19.1

7.30

102

14.3

25.5

13.7

95.8

21.5

32.4

20.6

95.8

ELISA试剂盒选择指南①②

1.

Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease. Baumeier C, Schluter L, Saussenthaler S, Laeger T, Rodiger M, Alaze SA, Fritsche L, Haring HU, Stefan N, Fritsche A, Schwenk RW, Schurmann A. Mol Metab. 2017 Oct;6(10):1254-1263.

 2.

Recombinant Mouse Osteocalcin Secreted by Lactococcus lactis Promotes Glucagon-Like Peptide-1 Induction in STC-1 Cells. Namai F, Shigemori S, Sudo K, Sato T, Yamamoto Y, Nigar S, Ogita T, Shimosato T. Curr Microbiol. 2017 Sep 13.

 3.

A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. Aoki R, Kamikado K, Suda W, Takii H, Mikami Y, Suganuma N, Hattori M, Koga Y. Sci Rep. 2017 Mar 2;7:43522.

 4.

Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model. Kishida Y, Okubo H, Ohno H, Oki K, Yoneda M. J Gastroenterol. 2017 Mar 27.

 5.

Fermented vegetable and fruit extract (OM-XŪ) stimulates murine gastrointestinal tract cells and RAW264. 7 cells in vitro and regulates liver gene expression in vivo. Wakame K, Nakata A, Sato K, Mihara Y, Takahata M, Miyake Y, Okada M, Shimomiya Y, and Komatsu K. Integr Mol Med, 2017 http://www.omx.co.jp/files/attachments/8e3f7824b69bece18acca14baf314b11.PDF

 6.

Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice. Yang JY, Lee YS, Kim Y, Lee SH, Ryu S, Fukuda S, Hase K, Yang CS, Lim HS, Kim MS, Kim HM, Ahn SH, Kwon BE, Ko HJ, Kweon MN. Mucosal Immunol. 2017 Jan;10(1):104-116

 7.

An extract from pork bones containing osteocalcin improves glucose metabolism in mice by oral administration. Mizokami A, Wang D, Tanaka M, Gao J, Takeuchi H, Matsui T, Hirata M. Biosci Biotechnol Biochem. 2016 Jul 27:1-8.

 8.

Catecholamines Facilitate Fuel Expenditure and Protect Against Obesity via a Novel Network of the Gut-Brain Axis in Transcription Factor Skn-1-deficient Mice. Ushiama S, Ishimaru Y, Narukawa M, Yoshioka M, Kozuka C, Watanabe N, Tsunoda M, Osakabe N, Asakura T, Masuzaki H, Abe K. EBioMedicine. 2016 Jun;8:60-71.

 9.

Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff. Koyama A, Komori K, Otsuka R, Kajikuri J, Itoh T. J Vasc Surg. 2016 May;63(5):1360-70.

10.

Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice. Salim HM, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, Soeki T, Shimabukuro M, Sata M. Vascul Pharmacol. 2016 Apr;79:16-23.

11.

Intestinal Bile Acid Composition Modulates Prohormone Convertase 1/3 (PC1/3) Expression and Consequent GLP-1 Production in Male Mice. Morimoto K, Watanabe M, Sugizaki T, Irie J, Itoh H. Endocrinology. 2016 Mar;157(3):1071-81.

12.

Total gastrectomy-induced reductions in food intake and weight are counteracted by rikkunshito by attenuating glucagon-like peptide-1 elevation in rats. Taguchi M, Dezaki K, Koizumi M, Kurashina K, Hosoya Y, Lefor AK, Sata N, Yada T. Surgery. 2016 Jan 13. pii: S0039-6060(15)01029-6

13.

DPP-4 inhibition has beneficial effects on the heart after myocardial infarction. Akihiko Kubota, Hiroyuki Takano, Haixiu Wang, Hiroshi Hasegawa, Hiroyuki Tadokoro, Masanori Hirose, Yuka Kobaraa, Tomoko Yamada-Inagawa, Issei Komuro, Yoshio Kobayashi. Journal of Molecular and Cellular Cardiology, Volume 91, Feb. 2016, Pages 72–80

14.

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: Effects on peripheral sensory nerve function, structure and molecular changes. Tsuboi K, Mizukami H, Inaba W, Baba M, Yagihashi S. J Neurochem. Volume 136, Issue 4, pages 859–870, Feb. 2016

15.

Intestinal Bile Acid Composition Modulates Prohormone Convertase 1/3 (PC1/3) Expression and Consequent GLP-1 Production in male mice. Morimoto K, Watanabe M, Sugizaki T, Irie JI, Itoh H. Endocrinology. 2016 Jan 20:en20151551.

16.

Hypoxia decreases glucagon-like peptide-1 secretion from the GLUTag cell line. Kihira Y, Burentogtokh A, Itoh M, Izawa-Ishizawa Y, Ishizawa K, Ikeda Y, Tsuchiya K, Tamaki T. Biol Pharm Bull. Vol.38(4), p514-21, 2015.

17.

Dietary obacunone supplementation stimulates muscle hypertrophy, and suppresses hyperglycemia and obesity through the TGR5 and PPARγ pathway. Horiba T, Katsukawa M, Mita M, Sato R. Biochem Biophys Res Commun. Vol.463(4), p846-52, Aug 2015.

18.

Combination of DPP-4 inhibitor and PPARγ agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression. Hirukawa H, Kaneto H, Shimoda M, Kimura T, Okauchi S, Obata A, Kohara K, Hamamoto S, Tawaramoto K, Hashiramoto M, Kaku K. Mol Cell Endocrinol. Jun 2015.

19.

Glucagon-like peptide-1 is specifically involved in sweet taste transmission. Takai S, Yasumatsu K, Inoue M, Iwata S, Yoshida R, Shigemura N, Yanagawa Y, Drucker DJ, Margolskee RF, Ninomiya Y. FASEB J. Vol.29(6), p2268-80, Jun 2015.

20.

Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice. Akita K, Isoda K, Shimada K, Daida H. J Am Heart Assoc. Vol.13;4(3):e001469, Mar 2015.

21.

Effects of sleeve gastrectomy and gastric banding on the hypothalamic feeding center in an obese rat model. Kawasaki T1, Ohta M, Kawano Y, Masuda T, Gotoh K, Inomata M, Kitano S.  Surg Today. 2015 Feb 28.

22.

Duodenal-jejunal bypass improves diabetes and liver steatosis via enhanced glucagon-like peptide-1 elicited by bile acids. Kashihara H, Shimada M, Kurita N, Sato H, Yoshikawa K, Higashijima J, Chikakiyo M, Nishi M, Takasu C. J Gastroenterol Hepatol. Vol.30(2), p308-15, Feb 2015.

23.

Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model. Okubo H, Nakatsu Y, Sakoda H, Kushiyama A, Fujishiro M, Fukushima T1, Matsunaga Y, Ohno H, Yoneda M, Kamata H, Shinjo T, Iwashita M, Nishimura F, Asano T. Am J Physiol Gastrointest Liver Physiol. Vol.15;308(2), G151-8, Jan 2015.

24.

Glucagon-like peptide-1 production in the GLUTag cell line is impaired by free fatty acids via endoplasmic reticulum stress. Hayashi H, Yamada R, Das SS, Sato T, Takahashi A, Hiratsuka M, Hirasawa N. Metabolism. Vol.63(6), p800-11. Jun 2014.

25.

MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice. Ohyama T, Sato K, Yamazaki Y, Hashizume H, Horiguchi N, Kakizaki S, Mori M, Kusano M, Yamada M. World J Gastroenterol.Vol.20(43), p16227-35, Nov 2014.

26.

Oral administration of osteocalcin improves glucose utilization by stimulating glucagon-like peptide-1 secretion. Mizokami A, Yasutake Y, Higashi S, Kawakubo-Yasukochi T, Chishaki S, Takahashi I, Takeuchi H, Hirata M. Bone. 16;69C:68-79. Sep 2014.

27.

Dietary sweet potato (Ipomoea batatas L.) leaf extract attenuates hyperglycaemia by enhancing the secretion of glucagon-like peptide-1 (GLP-1) . Nagamine R, Ueno S, Tsubata M, Yamaguchi K, Takagaki K, Hira T, Hara H, Tsuda T. Food Funct, Vol.5(9), p2309-2316, Aug 2014.

28.

Duodenal-jejunal bypass improves diabetes and liver steatosis via enhanced glucagon-like peptide-1 elicited by bile acids. Kashihara H, Shimada M, Kurita N, Sato H, Yoshikawa K, Higashijima J, Chikakiyo M, Nishi M, Takasu C. Journal of Gastroenterology and Hepatology, Aug 2014.

29.

Deletion of Hypoxia-Inducible Factor-1α in Adipocytes Enhances Glucagon-Like Peptide-1 Secretion and Reduces Adipose Tissue Inflammation. Kihira Y, Miyake M, Hirata M, Hoshina Y, Kato K, Shirakawa H, Sakaue H, Yamano N, Izawa-Ishizawa Y, Ishizawa K, Ikeda Y, Tsuchiya K, Tamaki T, Tomita S. PLoS One. 2014 Apr 4;9(4):e93856

30.

Glucagon-like peptide-1 production in the GLUTag cell line is impaired by free fatty acids via endoplasmic reticulum stress. Hayashi H., Yamada R., Shankar Das S., Sato T., Takahashi A., Hiratsuka M., Hirasawa N. Metabolism – Clinical and Experimental, 2014.

31.

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Kodera AR, Shikata K., Takatsuka T., Oda K., Miyamoto S., Kajitani N., Hirota D., Ono T., Usui HK., Makino H. Biochemical and Biophysical Research Communications, Vol.443(3), p828-833, Jan 2014.

32.

Novel insight into the distribution of L-cells in the rat intestinal tract. Hansen CF., Vrang N., Sangild PT., Jelsing J. Am J Transl Res, Vol.5(3), p347-358, 2013.

33.

Cinnamtannin A2, a Tetrameric Procyanidin, Increases GLP-1 and Insulin Secretion in Mice. Yamashita Y, Okabe M, Natsume M, Ashida H. Bioscience, Biotechnology, and Biochemistry , Vol.77(4), 2013

34.

The protective roles of GLP-1R signaling in diabetic nephropathy:possible mechanism and therapeutic potential. H.Fujita, T.Morii, H.Fujishima, T.Sato, T.Shimizu, M.Hosoba, K.Tsukiyama, T.Narita, T.Takahashi, D.J.Drucker, Y.Seino, and Y.Yamada. Kidney International, 2013

35.

Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice. K.Ishibashi., A.Hara., Y.Fujitani., T.Uchida., K.Komiya., M.Tamaki., H.Abe., T.Ogihara., A.Kanazawa., R.Kawamori and H.Watada. Biochem Biophys Res Commun, Vol.440(4), p570-575, Nov 2013.

36.

Vildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Hamamoto S, Kanda Y, Shimoda M, Tatsumi F, Kohara K, Tawaramoto K, Hashiramoto M and Kaku K. Diabetes, Obesity and Metabolism,Vol.15(2), p153-163, Feb 2013.

37.

Osteocalcin Induces Release of Glucagon-Like Peptide-1 and Thereby Stimulates Insulin Secretion in Mice. Mizokami A, Yasutake Y, Gao J, Matsuda M, Takahashi I, Takeuchi H and Hirata M. PLoS ONE 8(2): e57375. Feb 2013

38.

DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice. Shinobu Shimizu, Tetsuya Hosooka, Tomokazu Matsuda, Shun-ichiro Asahara, Maki Koyanagi-Kimura, Ayumi Kanno, Alberto Bartolome, Hiroaki Etoh, Megumi Fuchita, Kyoko Teruyama, Hiroaki Takahashi, Hiroyuki Inoue, Yusuke Mieda, Naoko Hashimoto, Susumu Seino, and Yoshiaki Kido. J Mol Endocrinol, Vol.49, p125-135, Oct 2012.

39.

Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. Inaba W, Mizukami H, Kamata K, Takahashi K, Tsuboi K and Yagihashi S. European Journal of Pharmacology,Vol.691(1-3), p297-306, Sep 2012.

40.

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice. Jacob Jelsing, Niels Vrang, Soren B van Witteloostuijn, Michael Mark and Thomas Klein. J Endocrinol, Vol.214, p381-387, Sep 2012.

41.

Neural and humoral changes associated with the adjustable gastric band: insights from a rodent model. J Kampe, A Stefanidis, S H Lockie, W A Brown, J B Dixon, A Odoi, S J Spencer, J Raven and B J Oldfield. International Journal of Obesity, 27 Mar 2012.

42.

Neural and humoral changes associated with the adjustable gastric band: insights from a rodent model. J Kampe, A Stefanidis, S H Lockie, W A Brown, J B Dixon, A Odoi, S J Spencer, J Raven and B J Oldfield. International Journal of Obesity, 27 Mar 2012.

43.

Mate Tea(Ilex paraguariensis)Promotes Satiety and Body Weight Lowering in Mice:Involvement of Glucagon-Like Peptide-1. G, M, E, Hussein., H, Matsuda., S, Nakamura., M, Hamao., T, Akiyama., K, Tamura., and M, Yoshikawa. Biol.Pharm.Bull. Vol.34(12), p1849-1855, 2011.

44.

5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion. R, Kogure., K, Toyama., S, Hiyamuta., I, Kojima., S, Takeda.  Biochemical and Biophysical Research Communications Vol.416(1-2), p58-63, 2011.

45.

GLP-1 Secretion in Response to Oral and Luminal Palatinose (Isomaltulose) in Rats. T,Hira.,M,Muramatsu.,M,Okuno.and H,Hara. J Nutr Sci Vitaminol, Vol.57, p30-35, 2011.

46.

Trehalose prevents adipocyte hypertrophy and mitigates insulin resistance. C,Arai.,N,Arai.,A,Mizote.,K,Kohno.,K,Iwaki.,T,Hanaya.,S,Arai.,S,Ushio.,S,Fukuda. Nutrition Research, Vol.30(12), p840-848, 2010.

47.

Imaging exocytosis of single glucagon-like peptide-1 containing granules in a murine enteroendocrine cell line with total internal reflection fluorescent microscopy. Ohara-Imaizumi,M.,Aoyagi,K.,Akimoto,Y.,Nakamichi,Y.,Nishiwaki,C.,Kawakami,H.and Nagamatsu,S. Biochemical and Biophysical Reseach Communications, Vol.390, p16-20, 2009.